Background: Digital technology can offer naturalistic, momentary assessments and interventions for people with schizophrenia, but as such no app has emerged as a gold standard. Our previous work asked people with schizophrenia and their caregivers on the acceptability and feasibility of the proposed smartphone app-based mental health platform, mindLAMP. Following up on this work, we examined patient attitudes towards the mindLAMP platform after one month of use in a longitudinal study, and how it varied compared to each person’s psychosis symptoms.
Methods: 16 participants with schizophrenia were prompted to use mindLAMP daily to monitor their mood, symptoms, and behavior, and to play cognitive games, while optionally accessing psychoeducation resources and mindfulness exercises. At baseline and after 1 month, participants were assessed on the Positive and Negative Syndrome Scale (PANSS). After 1 month, they completed a survey asking about platform-wide and activity-specific attitudes on a 5-point Likert scale. Linear regressions were used to assess attitudes towards the app as they varied by PANSS score.
Results: The mean response on mindLAMP attitude survey was Neutral (M = 3.17, SD = 0.61), as was the response for the subsets of platform-wide questions (M = 3.10, SD = 1.08) and activity-specific questions (M = 3.24, SD = 0.49). Using the mean PANSS score at both baseline and 1-month, (M = 55.81, SD = 8.01), we found that response to mindLAMP attitude questions did significantly vary by the PANSS scores (R2 = 0.63, F (1,14) = 23.74, p < 0.001), in an inverse relationship, as did the subset of platform-wide responses (R2 = 0.52, F(1,14) = 15.95, p = 0.001), but not the activity-specific ratings.
Conclusion: People with milder forms of schizophrenia may be more open to using a symptom tracking and cognitive assessment app as part of their care than people with worse symptoms, though more research must be done to understand long term engagement with the app, and its potential as an intervention delivery platform.
Live Zoom Session – March 9th
Tanvi Lakhtakia, BA, John Torous, MD, MBI
John Torous, MD, MBI